Annual Current Liabilities
$57.53 M
-$5.25 M-8.36%
September 30, 2024
Summary
- As of February 23, 2025, ENTA annual total current liabilities is $57.53 million, with the most recent change of -$5.25 million (-8.36%) on September 30, 2024.
- During the last 3 years, ENTA annual current liabilities has risen by +$21.36 million (+59.06%).
- ENTA annual current liabilities is now -8.36% below its all-time high of $62.79 million, reached on September 30, 2023.
Performance
ENTA Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$49.05 M
-$8.48 M-14.75%
December 31, 2024
Summary
- As of February 23, 2025, ENTA quarterly total current liabilities is $49.05 million, with the most recent change of -$8.48 million (-14.75%) on December 31, 2024.
- Over the past year, ENTA quarterly current liabilities has stayed the same.
- ENTA quarterly current liabilities is now -28.07% below its all-time high of $68.19 million, reached on June 30, 2023.
Performance
ENTA Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
ENTA Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -8.4% | 0.0% |
| 3 y3 years | +59.1% | 0.0% |
| 5 y5 years | +154.5% | 0.0% |
ENTA Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -8.4% | +92.9% | -28.1% | +113.3% |
| 5 y | 5-year | -8.4% | +154.5% | -28.1% | +156.3% |
| alltime | all time | -8.4% | +2577.3% | -28.1% | +2182.5% |
Enanta Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $49.05 M(-14.7%) |
| Sep 2024 | $57.53 M(-8.4%) | $57.53 M(-1.2%) |
| Jun 2024 | - | $58.23 M(+6.6%) |
| Mar 2024 | - | $54.61 M(-12.5%) |
| Dec 2023 | - | $62.41 M(-0.6%) |
| Sep 2023 | $62.79 M(+110.5%) | $62.79 M(-7.9%) |
| Jun 2023 | - | $68.19 M(+112.0%) |
| Mar 2023 | - | $32.17 M(+39.8%) |
| Dec 2022 | - | $23.00 M(-22.9%) |
| Sep 2022 | $29.83 M(-17.5%) | $29.83 M(+29.5%) |
| Jun 2022 | - | $23.04 M(-25.1%) |
| Mar 2022 | - | $30.74 M(-18.9%) |
| Dec 2021 | - | $37.89 M(+4.7%) |
| Sep 2021 | $36.17 M(+49.7%) | $36.17 M(+26.4%) |
| Jun 2021 | - | $28.62 M(+7.5%) |
| Mar 2021 | - | $26.62 M(+15.5%) |
| Dec 2020 | - | $23.04 M(-4.6%) |
| Sep 2020 | $24.16 M(+6.8%) | $24.16 M(+1.0%) |
| Jun 2020 | - | $23.91 M(+22.5%) |
| Mar 2020 | - | $19.52 M(+2.0%) |
| Dec 2019 | - | $19.14 M(-15.3%) |
| Sep 2019 | $22.61 M(+41.1%) | $22.61 M(+10.3%) |
| Jun 2019 | - | $20.50 M(+0.0%) |
| Mar 2019 | - | $20.49 M(-9.5%) |
| Dec 2018 | - | $22.63 M(+41.2%) |
| Sep 2018 | $16.02 M | $16.02 M(+14.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $14.03 M(-18.0%) |
| Mar 2018 | - | $17.12 M(-11.0%) |
| Dec 2017 | - | $19.22 M(-8.4%) |
| Sep 2017 | $20.98 M(+166.0%) | $20.98 M(+88.7%) |
| Jun 2017 | - | $11.12 M(+21.5%) |
| Mar 2017 | - | $9.15 M(+42.3%) |
| Dec 2016 | - | $6.43 M(-18.5%) |
| Sep 2016 | $7.89 M(+17.7%) | $7.89 M(-17.6%) |
| Jun 2016 | - | $9.57 M(-20.2%) |
| Mar 2016 | - | $11.99 M(+10.3%) |
| Dec 2015 | - | $10.87 M(+62.2%) |
| Sep 2015 | $6.70 M(+41.3%) | $6.70 M(-8.3%) |
| Jun 2015 | - | $7.31 M(-63.1%) |
| Mar 2015 | - | $19.79 M(-0.4%) |
| Dec 2014 | - | $19.87 M(+318.6%) |
| Sep 2014 | $4.75 M(+4.9%) | $4.75 M(+11.2%) |
| Jun 2014 | - | $4.27 M(-3.4%) |
| Mar 2014 | - | $4.42 M(+72.1%) |
| Dec 2013 | - | $2.57 M(-43.3%) |
| Sep 2013 | $4.53 M(-21.1%) | $4.53 M(+53.9%) |
| Jun 2013 | - | $2.94 M(-40.6%) |
| Mar 2013 | - | $4.95 M(+31.3%) |
| Dec 2012 | - | $3.77 M(-34.2%) |
| Sep 2012 | $5.73 M(+166.8%) | $5.73 M(+46.2%) |
| Jun 2012 | - | $3.92 M(+82.5%) |
| Sep 2011 | $2.15 M | $2.15 M |
FAQ
- What is Enanta Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals annual current liabilities year-on-year change?
- What is Enanta Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly current liabilities year-on-year change?
What is Enanta Pharmaceuticals annual total current liabilities?
The current annual current liabilities of ENTA is $57.53 M
What is the all time high annual current liabilities for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high annual total current liabilities is $62.79 M
What is Enanta Pharmaceuticals annual current liabilities year-on-year change?
Over the past year, ENTA annual total current liabilities has changed by -$5.25 M (-8.36%)
What is Enanta Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of ENTA is $49.05 M
What is the all time high quarterly current liabilities for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high quarterly total current liabilities is $68.19 M
What is Enanta Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, ENTA quarterly total current liabilities has changed by $0.00 (0.00%)